2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5879 In vivo generation of HIV-specific CAR-T cells using CD3-targeted lentiviral particles

Kasey Chelemedos, DO, MPH, Erin Cole, PhD2, Marta Santos Bravo, PhD3, Gregory Sowd4, Ying Xiong, PhD5, Zhongyu Zhu6, Jian Hua Zheng7, Boro Dropulic, PhD, MBA8, Yanping Xie9, Maggie Yates10, Harris Goldstein, MD11
1 Albert Einstein College of Medicine, Bronx, New York, United States, The Children's Hospital at Montefiore, Bronx, New York, United States
2 Albert Einstein College of Medicine, Bronx, New York, United States
3 Albert Einstein College of Medicine, Bronx, New York, United States
4 Caring Cross, Gaithersburg, Maryland, United States
5 Caring Cross, Gaithersburg, Maryland, United States
6 Caring Cross, Gaithersburg, Maryland, United States
7 Albert Einstein College of Medicine, Bronx, New York, United States
8 Caring Cross, Gaithersburg, Maryland, United States
9 Caring Cross, Gaithersburg, Maryland, United States
10 Caring Cross, Gaithersburg, Maryland, United States
11 Albert Einstein College of Medicine, Bronx, New York, United States
CAR-T cell therapies are limited by complex ex vivo manufacturing and high production costs, thereby motivating the development of in vivo gene-delivery strategies. In this study, we developed and evaluated a novel targeted lentiviral particle (LVP) that selectively delivers an HIV-bispecific duoCAR to T cells. This platform uses a receptor-blinded, mutagenized Cocal glycoprotein-pseudotyped LVP that displays an anti-CD3 single-chain variable fragment (scFv) targeting domain and co-expresses an anti-CD28 costimulatory domain, enabling selective activation and transduction of CD3⁺ T cells. Effective lentiviral delivery was achieved both in vitro and in vivo with LVP administration, without prior T cell activation, resulting in circulating CAR-T cell frequencies of approximately 2–3% in a humanized mouse model. The CD3-targeting LVP (CX057/CX304; CX304) demonstrated superior targeting efficiency compared to both a traditional lentiviral vector pseudotyped with the wild-type Cocal envelope (CX057/CX004; CX004) and a control vector pseudotyped solely with the blinded Cocal envelope (CX057/CX303; CX303). Importantly, delivering the HIV-specific duoCAR via CX304 generated polyfunctional CAR-T cells that released inflammatory cytokines in response to HIV antigen and effectively suppressed HIV-1 clade B infection from two viral strains in vitro. Overall, these findings demonstrate the potential of targeted lentiviral delivery to pan-T cell subsets and support in vivo CAR-T cell production as a promising therapy for HIV treatment. 
Kasey Chelemedos, DO, MPH: No relevant conflicts of interest to declare.